| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 1/50-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | SMAC; DFNA64; DIABLO; SMAC3 |
| Entrez GeneID | 56616 |
| WB Predicted band size | Calculated MW: 27 kDa; Observed MW: 21 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human Smac/Diablo |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于SMAC抗体的3篇代表性文献及其摘要概括：
---
1. **文献名称**：*Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition*
**作者**：Du C, Fang M, Li Y, et al.
**摘要**：该研究首次鉴定了SMAC(Diablo)蛋白，揭示了其通过拮抗凋亡抑制蛋白(IAPs)促进caspase活化的机制。实验表明，SMAC在细胞凋亡时从线粒体释放，与XIAP等IAPs结合，解除其对caspase-9的抑制，从而触发凋亡信号通路。
---
2. **文献名称**：*Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins*
**作者**：Verhagen AM, Ekert PG, Pakusch M, et al.
**摘要**：本文独立发现了SMAC/DIABLO蛋白，解析其与IAPs(如XIAP、c-IAP1)的相互作用，证明其通过N端AVPI基序结合IAPs的BIR结构域，阻断IAPs对caspase的抑制作用，为开发靶向IAP的抗癌策略奠定基础。
---
3. **文献名称**：*Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo*
**作者**：Fulda S, Wick W, Weller M, et al.
**摘要**：研究利用SMAC模拟物(小分子化合物)联合TRAIL或化疗药物，增强胶质瘤细胞凋亡敏感性。实验证明SMAC抗体可用于检测内源性SMAC水平，并验证模拟物通过模拟SMAC功能抑制IAPs，显著提高肿瘤细胞对治疗的响应。
---
**备注**：SMAC抗体的研究多集中于其功能机制及模拟物开发，直接以“SMAC抗体”为核心的研究较少，上述文献为相关领域奠基性工作，可为抗体应用提供理论支撑。如需更近期文献，建议在PubMed中以“SMAC antibody”或“DIABLO antibody”为关键词检索。
**Background of SMAC Antibodies**
SMAC (Second Mitochondrial Activator of Caspases), also known as DIABLO, is a pro-apoptotic protein released from mitochondria during apoptosis. It promotes cell death by neutralizing Inhibitor of Apoptosis Proteins (IAPs), such as XIAP, which block caspase activity. In cancer, dysregulated apoptosis often stems from overexpression of IAPs, enabling tumor survival. SMAC mimetics, small molecules mimicking SMAC’s IAP-binding domain, have emerged as therapeutic agents to restore apoptosis in malignant cells by displacing caspases from IAPs.
SMAC antibodies are critical tools for detecting endogenous SMAC levels in research, aiding studies on mitochondrial apoptosis pathways and their dysfunction in diseases. Therapeutically, SMAC-targeting antibodies are explored to enhance cancer treatment efficacy, either alone or combined with chemotherapy/radiation. Some SMAC-based agents are in clinical trials, highlighting their potential to overcome IAP-mediated resistance. Additionally, SMAC antibodies help identify biomarkers for patient stratification, linking SMAC expression to apoptotic capacity and treatment response.
Overall, SMAC antibodies bridge diagnostic and therapeutic innovation, offering insights into apoptosis mechanisms and advancing targeted cancer therapies.
×
